Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms

Completed

• Conditions: Refractory Cancer Pain; Intrathecal Analgesia

• Registration Number: NCT04491123
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Intrathecal analgesia is used in refractory cancer pain because of drug sides effects or intractable pain. The aim of this approach is to improve pain management, and also to improve patient comfort. This study will assess patient discomfort symptoms before and after setting up intrathecal analgesia.

Detailed Description

Descriptive multicenter study including patients with refractory cancer pain (unmanageable drug sides effects or intractable pain) who will receive intrathecal analgesia Patient discomfort symptoms will be evaluated before and after the beginning of intrathecal analgesia at 15, 30, 60 and 90 days.

Moreover, the impact on patient close relatives and on return home will be assessed.

Study Timeline

• Study Start: 2018-11-01
• Study First Submitted: 2020-03-11
• Primary Completion: 2020-04-30
• Study Completion: 2020-06-30
• Status Verified: 2020-07
• Study First Submitted QC: 2020-07-28
• Last Update Submitted: 2020-07-28
• Study First Posted: 2020-07-29
• Last Update Posted: 2020-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number Evaluation of Edmonton symptoms	up to 90 days after patient inclusion	Edmonton symptom assessment system

Secondary Outcome Measures

Name	Time	Method
Autonomy assessment score for activities of daily living	1 day	Autonomy assessment score for activities of daily living

Trial Locations

Locations (1)

Uhmontpellier; 🇫🇷 Montpellier, France